Female n(%) | 38 (69.1) |
New onset n(%) | 48 (87.3) |
Age at onset (years) median (IQR) | 4.8 (2.2; 10.0) |
Age at MTX start (years) median (IQR) | 5.3 (2.8; 10.6) |
Interval from onset to MTX start (months) median (IQR) | 3.8 (2.5; 6.4) |
JIA subtype n | |
  – Oligoarthritis: persistent/extended | 18/3 (32.7 %/5.5 %) |
  – Polyarthritis (RF positive n = 1) | 25 (45.5 %) |
  – Systemic with polyarthritis | 5 (9.1 %) |
  – Enthesitis-related | 3 (5.5 %) |
  – Psoriatic | 1(1.8 %) |
Parent/patient global assessment of well-being mm, median (IQR) | 27 (15; 40) |
CHAQ 0–3 median (IQR) | 0.25 (0.13; 0.69) |
ESR mm/h median (IQR) | 23 (15; 35) |
MTX dose mg/m2 /week median (IQR) | 14.2 (12.1;15.2) |
  – s.c. (n = 45) | 14.4 (13.3; 15.9) |
  – p.o. (n = 10) | 11.7 (8.3; 12.5) |
Concomitant therapy n(%) | |
  – IATHa | 21 (38.2) |
  – Sulphasalazine | 1 (1.8) |
  – Systemic corticosteroids | 9 (16.4) |
  – Folic acid 5–10 mg/weekb | 55 (100) |